Back to School: How biopharma can reboot drug development. Access exclusive analysis here

rhuMAb-VEGF: Phase II

DNA reported preliminary data from its 104-patient, open label study of rhuMAb-VEGF in combination with 5-fluorouracil (5-FU)/leucovorin, showing

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE